spacer
home > ebr > summer 2004 > maximise the return on ethics consultations by minimising deficit thinking
PUBLICATIONS
European Biopharmaceutical Review

Maximise the Return on Ethics Consultations by Minimising Deficit Thinking

It has become commonplace for representatives from industry to be involved in discussions about the broader social issues surrounding science and technology. For many people this may involve requests to participate in public engagement exercises, ethical consultations and policy-making procedures. These exercises are designed to create transparent and engaged relationships between science, industry and the public. They are imagined to hold potential commercial benefits that include the promotion of novel technologies in society, as well as the fostering of public confidence in industry. However, achieving these gains is contingent upon confronting the complex relationship between science and society. In this article, we will examine how deeply embedded assumptions about knowledge and expertise may curtail the potential to achieve positive outcomes through participation and engagement.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Andrew Smart, Sociology Research Officer for the Oxford Genetics Knowledge Park and Dr Kevin E Jones, Senior Research Associate with the Programme on Understanding Risk at Brunel University

Dr Andrew Smart is the Sociology Research Officer for the Oxford Genetics Knowledge Park, based at The Ethox Centre, University of Oxford. His work is focused on the social aspects of human genetics research. He is currently exploring the social implications of translating genetics research into clinical practice. In his previous research, he has examined the commercial and clinical development of pharmacogenetics, and mass media coverage of the ethical, legal and social implications of human genetics.


Dr Kevin E Jones is a Senior Research Associate with the Programme on Understanding Risk at Brunel University. His current research investigates the relationship between social exclusion and public perceptions of risk and science. Kevin has written widely on a variety of scientific controversies, including the debate over agricultural biotechnology, the management of BSE in the UK and the introduction of growth hormones in the North American dairy industry.

spacer
Dr Andrew Smart
spacer
spacer
spacer
Dr Kevin E Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

Why You Should Be Using Ultrasonic Cleaning

Natoli Engineering Company, Inc.

Clean punches and dies are essential to maintaining the integrity and efficiency of your tooling investment, as well as the quality of your product. Ultrasonic cleaning has long been considered the most effective, nondestructive way to clean tools – from medical instruments to tablet tooling. The Tableting Specification Manual (TSM) states, “An ultrasonic bath is ideal for cleaning tooling.” This high-tech cleaning process also saves time, reduces cost and is better for the environment.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement